X
[{"orgOrder":0,"company":"Inotrem","sponsor":"Roche Diagnostics GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Inotrem Secures Strategic Licensing Agreement for a Companion Diagnostics Test in Septic Shock","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase II","country":"FRANCE","productType":"Peptide","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Peptide","graph2":"Inotrem"}]
Find Drugs for Trauma (Emergency, Injury, Surgery) in Phase II Clinical Development in FRANCE
Filters
Details:
Inotrem entered a worldwide licensing agreement with Roche Diagnostics for the commercialization of a mechanism-based companion diagnostic test using a soluble plasma protein.
Lead Product(s):
Nangibotide
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Peptide
Partner/Sponsor/Collaborator:
Roche Diagnostics GmbH
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
January 21, 2020